Trends in co-prescribing of renin-angiotensin system (RAS)-acting agents in France, Germany and the UK during 2001 -2012

Study identification

• EU PAS number:
  EUPAS4389
• Study ID:
  33362
• Official title and acronym:
  Trends in co-prescribing of renin-angiotensin system (RAS)-acting agents in France, Germany and the UK during 2001 -2012
• DARWIN EU® study:
  No
• Study countries:
  France

  Germany

  United Kingdom
• Study description:
  The present study aims to describe the extent and the patterns of co-prescription of RAS-acting agents in three large EU countries in the period 2001-2012 including in patients with diabetes mellitus (DM) and chronic kidney disease (CKD). This will be done using the European Medicines Agency’s in-house IMS Health databases. Co-prescription will be defined as the prescription of different drug classes made on the same day and by the same physician. By reason of the large populations in the three study countries, which approximate to 40% of the total EU population, these population-based data may contribute to the assessment of the public health impact of any safety concern in relation to the co-prescription of RAS-acting agents in the EU.
• Study status:
  Finalised

Research institutions and networks

Institutions

European Medicines Agency (EMA)

Study timelines

Date when funding contract was signed

Planned: 22/07/2013

Actual: 22/07/2013

Study start date

Planned: 31/07/2013

Actual: 31/07/2013

Date of final study report

Planned: 02/09/2013

Actual: 27/08/2013

Sources of funding

EMA

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable